Understand the source comparison
Klow Half-Life: Peptide and Study Design Comparison
Klow (subcutaneous) 6–8 hours 12–16 hours in muscle/liver 4–6 hours for acute effects; 12–24 hours for transcriptional endpoints Every 12–24 hours Best for mitochondrial studies requiring stable tissue exposure without continuous plasma saturation MOTS-c (comp
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Klow (subcutaneous)
- 6–8 hours
- 12–16 hours in muscle/liver
- 4–6 hours for acute effects; 12–24 hours for transcriptional endpoints
- Every 12–24 hours
- Best for mitochondrial studies requiring stable tissue exposure without continuous plasma saturation
- MOTS-c (comparison peptide)
- 4–6 hours
- 8–12 hours
- 2–4 hours for immediate metabolic markers
- Every 8–12 hours
- Shorter half-life requires more frequent dosing but allows tighter temporal control in acute studies
- Single-dose acute study
- Clears by 24 hours
- Within 6 hours post-dose
- One-time administration
- Suitable for proof-of-concept and dose-response characterization
- Chronic dosing protocol (7–14 days)
- Steady-state after 5–7 days
- Cumulative tissue saturation
- Anytime during steady-state window
- Daily administration
- Required for mitochondrial biogenesis, metabolic adaptation, and sustained outcome measures
- Room temperature storage (reconstituted)
- N/A. Stability issue
- Degrades 15–20% per 6 hours
- N/A
- Avoid entirely. Refrigeration at 2–8°C is non-negotiable for maintaining advertised potency